Literature DB >> 11722811

The New Age of Prostatitis.

Granville L. Lloyd1, Anthony J. Schaeffer.   

Abstract

Prostatitis has long been a poorly understood and poorly characterized entity. Characterized in 1980 as a "wastebasket of clinical ignorance," it has only recently begun to be studied effectively. Prostatitis represents over 2 million medical office visits per year in the United States, and is the diagnosis given to 8% of urology clinic patients. Its prevalence may be as high as 10% among the male population at large. Sufferers report a sickness impact of prostatitis that is similar to myocardial infarction or Crohn's disease. Less than 10% of cases of prostatitis are easily demonstrable to have a bacterial cause; these respond to conventional antimicrobial treatment. The etiology, pathogenesis, and optimum treatment for the remaining 90% of sufferers of this disease complex are quite unclear. Application of clinical research techniques and molecular biology promise new insight into this challenging and difficult problem.

Entities:  

Year:  2001        PMID: 11722811     DOI: 10.1007/s11908-001-0091-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  34 in total

1.  Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.

Authors:  J M Potts
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  Allopurinol for prostatitis: where is the evidence?

Authors:  J C Nickel; D R Siemens; M J Lundie
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

Review 3.  The Pre and Post Massage Test (PPMT): a simple screen for prostatitis.

Authors:  J C Nickel
Journal:  Tech Urol       Date:  1997

4.  Sickness impact of chronic nonbacterial prostatitis and its correlates.

Authors:  K Wenninger; J R Heiman; I Rothman; J P Berghuis; R E Berger
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

Review 5.  Diagnosis and treatment of chronic abacterial prostatitis: a systematic review.

Authors:  M McNaughton Collins; R MacDonald; T J Wilt
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

6.  The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network.

Authors:  M S Litwin; M McNaughton-Collins; F J Fowler; J C Nickel; E A Calhoun; M A Pontari; R B Alexander; J T Farrar; M P O'Leary
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

7.  Detection of bacterial signal by 16S rRNA polymerase chain reaction in expressed prostatic secretions predicts response to antibiotic therapy in men with chronic pelvic pain syndrome.

Authors:  D A Shoskes; A R Shahed
Journal:  Tech Urol       Date:  2000-09

8.  Psychological and physical factors involved in chronic idiopathic prostatitis.

Authors:  J P Berghuis; J R Heiman; I Rothman; R E Berger
Journal:  J Psychosom Res       Date:  1996-10       Impact factor: 3.006

9.  Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.

Authors:  J J de la Rosette; H F Karthaus; P E van Kerrebroeck; T de Boo; F M Debruyne
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

10.  Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires.

Authors:  J C Nickel; R Sorensen
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

View more
  1 in total

1.  Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10 ng/mL?

Authors:  W F S Busato; G L Almeida; Jamylle Geraldo; F S Busato
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.